Free Publications

Search for cll returned 193 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

Transcript

Hello, everyone, and welcome to NHL and CLL–Diagnosis and Treatment Update, a free telephone web education program. It is my pleasure to introduce your moderator Lauren Berger of The Leukemia & Lymphoma Society.

  • PDF
Read more

Strengthening the Quality of CLL Care Among Clinical Teams and Health Systems

November 30, 2017

In collaboration with PRIME®
  Click Here to Participate CE Credit Available Until: 11/29/18 1 AMA PRA Category 1 CreditTM/1 ACPE credit for pharmacists/ 1 CE contact hour for nurses and case managers

  Learning Objectives Upon completion of this activity, participants will be able to: Assess common gaps in guideline-directed, coordinated, and patient-centered care for patients with CLL Evaluate the ap ...

  • Photo
Read more

LLS Applauds Data From Phase 2 Study of Venetoclax for High-Risk CLL Patients

LLS has supported this research for 13 years through its Specialized Center of Research Program

White Plains, N.Y. (August 19, 2015) – The Leukemia & Lymphoma Society (LLS) welcomes the news that an investigational therapy to treat patients with a high-risk subset of chronic lymphocytic leukemia (CLL) has shown very positive results in a Phase II clinical trial. There are more than 126,000 patients in the United States currently living with CLL, a typically slow-moving blo ...

  • Photo
Read more

LLS Applauds Approval of New Therapy for CLL Patients

Development of the drug, venetoclax, was supported by LLS funding

Rye Brook, NY – April 12, 2016 – The approval of a new therapy for patients with a high-risk form of chronic lymphocytic leukemia (CLL) is welcome news for patients for whom there have been few other options, The Leukemia & Lymphoma Society (LLS) said today. The U.S. Food and Drug Administration has approved venetoclax (Venclexta ®) to treat patients with a rare subset of CLL in which a piece of chromosome ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.